There have been few acquisitions in the hemodynamics monitoring space recently, but Masimo Corp.’s $40.3m cash offer for the UK-based LiDCO Group Plc is a good fit, according to BTIG analyst Marie Thibault.
“Lidco’s technology is complementary to Masimo’s Pleith Variabilty Index and SpHb total hemoglobin monitoring parameters, so should add to clinician efforts to optimize goal-directed therapy and enhanced recovery after surgery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?